News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
389,973 Results
Type
Article (25377)
Company Profile (33)
Press Release (364560)
Multimedia
Podcasts (129)
Webinars (16)
Section
Business (122261)
Career Advice (1474)
Deals (17791)
Drug Delivery (81)
Drug Development (43881)
Employer Resources (100)
FDA (9043)
Job Trends (8720)
News (195480)
Policy (17698)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (1505)
Academic (1)
Accelerated approval (23)
Adcomms (16)
Allergies (105)
Alliances (33814)
ALS (125)
Alzheimer's disease (1057)
Antibody-drug conjugate (ADC) (270)
Approvals (9325)
Artificial intelligence (415)
Autoimmune disease (158)
Automation (36)
Bankruptcy (161)
Best Places to Work (7191)
BIOSECURE Act (12)
Biosimilars (125)
Biotechnology (27)
Bladder cancer (131)
Brain cancer (39)
Breast cancer (463)
Cancer (3661)
Cardiovascular disease (320)
Career advice (1274)
Career pathing (33)
CAR-T (158)
CDC (38)
Cell therapy (508)
Cervical cancer (29)
Clinical research (38311)
Collaboration (1471)
Company closure (3)
Compensation (321)
Complete response letters (35)
COVID-19 (1604)
CRISPR (68)
C-suite (545)
Cystic fibrosis (88)
Data (4948)
Decentralized trials (3)
Denatured (42)
Depression (95)
Dermatology (39)
Diabetes (377)
Diagnostics (3735)
Digital health (30)
Diversity (7)
Diversity, equity & inclusion (30)
Drug discovery (201)
Drug pricing (128)
Drug shortages (21)
Duchenne muscular dystrophy (174)
Earnings (59264)
Editorial (48)
Employer branding (14)
Employer resources (88)
Events (58695)
Executive appointments (606)
FDA (11299)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (9)
Frontotemporal dementia (23)
Funding (941)
Gene editing (139)
Generative AI (44)
Gene therapy (452)
GLP-1 (651)
Government (2570)
Grass and pollen (6)
Guidances (336)
Healthcare (10381)
HIV (56)
Huntington's disease (34)
IgA nephropathy (64)
Immunology and inflammation (165)
Immuno-oncology (63)
Indications (122)
Infectious disease (1792)
Inflammatory bowel disease (139)
Inflation Reduction Act (14)
Influenza (72)
Intellectual property (171)
Interviews (273)
IPO (8503)
IRA (36)
Job creations (1837)
Job search strategy (1030)
JPM (46)
Kidney cancer (14)
Labor market (59)
Layoffs (302)
Leadership (33)
Legal (4526)
Liver cancer (54)
Longevity (18)
Lung cancer (519)
Lymphoma (294)
Machine learning (31)
Management (34)
Manufacturing (591)
MASH (134)
Medical device (6916)
Medtech (6963)
Mergers & acquisitions (10038)
Metabolic disorders (944)
mRNA (123)
Multiple sclerosis (128)
NASH (9)
Neurodegenerative disease (238)
Neuropsychiatric disorders (57)
Neuroscience (1936)
NextGen: Class of 2026 (3484)
Non-profit (2735)
Now hiring (13)
Obesity (419)
Opinion (223)
Ovarian cancer (108)
Pain (137)
Pancreatic cancer (157)
Parkinson's disease (207)
Partnered (21)
Patents (327)
Patient recruitment (311)
Peanut (31)
People (30037)
Pharmaceutical (11)
Pharmacy benefit managers (17)
Phase 1 (11516)
Phase 2 (16373)
Phase 3 (13711)
Pipeline (5292)
Policy (204)
Postmarket research (1690)
Preclinical (4960)
Press Release (31)
Prostate cancer (229)
Psychedelics (31)
Radiopharmaceuticals (191)
Rare diseases (649)
Real estate (2661)
Recruiting (39)
Regulatory (13609)
Reports (27)
Research institute (1408)
Resumes & cover letters (224)
Rett syndrome (21)
RNA editing (11)
RSV (58)
Schizophrenia (104)
Series A (170)
Series B (104)
Service/supplier (3)
Sickle cell disease (76)
Special edition (16)
Spinal muscular atrophy (82)
Sponsored (29)
Startups (1625)
State (1)
Stomach cancer (15)
Supply chain (65)
Tariffs (53)
The Weekly (85)
Vaccines (708)
Venture capital (59)
Weight loss (252)
Women's health (64)
Worklife (17)
Date
Today (124)
Last 7 days (475)
Last 30 days (1947)
Last 365 days (19542)
2026 (5087)
2025 (19357)
2024 (20668)
2023 (22753)
2022 (29304)
2021 (31033)
2020 (30170)
2019 (25778)
2018 (19046)
2017 (18059)
2016 (17473)
2015 (19906)
2014 (16595)
2013 (14521)
2012 (14385)
2011 (13849)
2010 (13074)
Location
Africa (576)
Alabama (65)
Alaska (5)
Arizona (141)
Arkansas (7)
Asia (22753)
Australia (3832)
California (7288)
Canada (2145)
China (780)
Colorado (347)
Connecticut (369)
Delaware (230)
Europe (54167)
Florida (1214)
Georgia (248)
Hawaii (1)
Idaho (23)
Illinois (554)
India (59)
Indiana (396)
Iowa (10)
Japan (349)
Kansas (75)
Kentucky (20)
Louisiana (14)
Maine (32)
Maryland (898)
Massachusetts (5352)
Michigan (216)
Minnesota (327)
Mississippi (3)
Missouri (61)
Montana (12)
Nebraska (9)
Nevada (87)
New Hampshire (38)
New Jersey (2367)
New Mexico (13)
New York (2060)
North Carolina (975)
North Dakota (5)
Northern California (3565)
Ohio (189)
Oklahoma (15)
Oregon (21)
Pennsylvania (1579)
Puerto Rico (8)
Rhode Island (28)
South America (780)
South Carolina (33)
Southern California (2965)
Tennessee (140)
Texas (1150)
United States (26709)
Utah (242)
Vermont (1)
Virginia (168)
Washington D.C. (56)
Washington State (599)
West Virginia (3)
Wisconsin (68)
Wyoming (2)
389,973 Results for "merck sharp and dohme".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cardiovascular disease
Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher
Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.
March 31, 2026
·
2 min read
·
Tristan Manalac
Patents
Merck’s Keytruda Likely Has a Few Extra Years of Dominance, With Billions on the Line
Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts Bloomberg Intelligence, translating to some $22 billion more in revenue.
February 24, 2026
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms
Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiration of its blockbuster’s patents.
March 25, 2026
·
3 min read
·
Tristan Manalac
Executive appointments
Merck Reorganizes Human Health Work Into Two New Units
The new structure will help Merck as it slides toward a loss of exclusivity for Keytruda, pharma’s best-selling drug.
February 23, 2026
·
1 min read
·
Annalee Armstrong
Bladder cancer
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with muscle-invasive bladder cancer, even those eligible for cisplatin treatment.
March 2, 2026
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Merck Pushes Winrevair Past Dose-Response Doubts Into Pivotal Study for Rare Type of Heart Failure
The lack of a dose-response effect could be due to the high number of dropouts in the higher-dose Winrevair arm and the relatively small study population, a discussant for Merck explained.
March 30, 2026
·
2 min read
·
Tristan Manalac
HIV
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data
At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.
February 26, 2026
·
2 min read
·
Tristan Manalac
Earnings
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO Robert Davis called “probably the broadest and widest pipeline we’ve had in years.”
February 3, 2026
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
Merck had previously offered anywhere from $28 billion to $32 billion to swallow Revolution Medicines.
January 26, 2026
·
1 min read
·
Tristan Manalac
Mergers & acquisitions
Revolution Knows Its Worth as Merck Backs Off—For Now
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck backs off.
January 26, 2026
·
4 min read
·
Annalee Armstrong
1 of 38,998
Next
